Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials
详细信息 查看全文
- 作者：Victor Bitona ; vbiton@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Antonio Gil-Nagelb ; agnagel@ruberinternacional.es" class="auth_mail" title="E-mail the corresponding author ; Jouko Isojarvic ; 1 ; jouko.isojarvi@oulu.fi" class="auth_mail" title="E-mail the corresponding author ; Pamela Dotyc ; pamela.doty@ucb.com" class="auth_mail" title="E-mail the corresponding author ; David Hebertc ; david.hebert@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Nathan B. Fountaind ; NBF2P@hscmail.mcc.virginia.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Lacosamide ; Partial-onset seizures ; Safety ; Tolerability
- 刊名：Epilepsy & Behavior
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：52
- 期：part_PA
- 页码：119-127
- 全文大小：443 K
文摘
- •
Pooled analysis extends findings of lacosamide safety as add-on in partial seizures.
- •
The most common lacosamide-associated TEAEs were dizziness, nausea, and diplopia.
- •
TEAEs were dose-related, with the best tolerability at dosages of 200–400 mg/day.
- •
Incidence of TEAEs was higher during the titration phase than the maintenance phase.
- •
Few TEAEs were related to rash, weight change, psychiatric disturbances, or seizures.